Cytokinetics Inc CYTK:NASDAQ

Last Price$50.30NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/12/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$47.54 (3)
Ask (Size)$52.50 (49)
Day Low / HighN/A - N/A
Volume850.6 K
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 08/12/2022

 

Cytokinetics Inc ( NASDAQ )

Price: $50.30
Change: +0.83 (1.68%)
Volume: 850.6 K
4:00PM ET 8/12/2022
 
 

Global Blood Therapeutics Inc ( NASDAQ )

Price: $66.75
Change: +0.18 (0.27%)
Volume: 5.8 M
4:00PM ET 8/12/2022
 
 

Intra-Cellular Therapies Inc ( NASDAQ )

Price: $53.57
Change: -3.45 (6.05%)
Volume: 1.5 M
4:00PM ET 8/12/2022
 
 

Intellia Therapeutics Inc ( NASDAQ )

Price: $67.74
Change: +2.14 (3.26%)
Volume: 813.8 K
4:00PM ET 8/12/2022
 
 

Turning Point Therapeutics Inc ( NASDAQ )

Price: $75.40
Change: +0.40 (0.53%)
Volume: 1.7 M
4:00PM ET 8/12/2022
 

Read more news Recent News

--Oppenheimer Adjusts Cytokinetics Price Target to $60 From $57, Maintains Outperform Rating
10:26AM ET 8/10/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Raymond James Raises Cytokinetics Price Target to $63 From $54, Maintains Outperform Rating
11:02AM ET 8/05/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Cytokinetics Q2 Net Loss Narrows as Revenue Climbs; Shares Rise
10:27AM ET 8/05/2022 MT Newswires

Cytokinetics (CYTK) reported a Q2 net loss late Thursday of $0.23 per diluted share, compared with a loss of $0.86 a year earlier. Analysts polled by...

-- Earnings Flash (CYTK) CYTOKINETICS INCORPORATED Reports Q2 Revenue $89M
4:00PM ET 8/04/2022 MT Newswires

...

Company Profile

Business DescriptionCytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA. View company web site for more details
Address350 Oyster Point Boulevard
South San Francisco, California 94080
Phone+1.650.624.3000
Number of Employees130
Recent SEC Filing08/08/20224
President, Chief Executive Officer & DirectorRobert I. Blum
Vice President-Development OperationsEric Terhaerdt
Chief Financial Officer & Senior Vice PresidentChing W. Jaw
Executive Vice President-Research & DevelopmentFady Ibraham Malik

Company Highlights

Price Open$50.30
Previous Close$49.47
52 Week Range$29.10 - 54.74
Market Capitalization$4.7 B
Shares Outstanding94.1 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement11/02/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.57
Beta vs. S&P 500N/A
Revenue$31.5 M
Net Profit Margin-142.85%
Return on Equity-119.86%

Analyst Ratings as of 01/31/2022

Buy
11
Overweight
2
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset